✦ LIBER ✦

Exploring the use of a co-formulated pharmacological chaperone AT2220 with recombinant human acid alpha-glucosidase for Pompe disease

✍ Scribed by Khanna, Richie; Xu, Su; Lun, Yi; Soska, Rebecca; Feng, Jessie; Frascella, Michelle; Garcia, Anadina; Flanagan, John; Lockhart, David; Valenzano, Kenneth

Book ID: 122502312
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 57 KB
Volume: 108
Category: Article
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2012.11.126

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.17.8 The co-formulation of pharmacolog

P.17.8 The co-formulation of pharmacological chaperone AT2220 with recombinant human acid alpha-glucosidase improves enzyme uptake and glycogen reduction in a mouse model of Pompe disease

✍ Khanna, R.; Xu, S.; Pellegrino, L.; Lun, Y.; Soska, R.; Feng, J.; Frascella, M.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Subcutaneous administration of recombina

Subcutaneous administration of recombinant human acid α-glucosidase co-formulated with the pharmacological chaperone AT2220 leads to lysosomal uptake of rhGAA and glycogen reduction in disease-relevant tissues of mice with Pompe disease

✍ Lun, Yi; Pellegrino, Lee; Xu, Su; Feng, Jessie; Soska, Rebecca; Frascella, Miche 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Exploring the Use of Pharmacological Cha

Exploring the Use of Pharmacological Chaperone AT3375 Alone and in Combination with Recombinant human ß-Glucosidase for Gaucher Disease

✍ Richie Khanna; Lee Pellegrino; Rebecca Soska; Yi Lun; Jessie Feng; Michelle Fras 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

G.P.8.05 The pharmacological chaperone A

G.P.8.05 The pharmacological chaperone AT2220 increases mutant acid alpha-glucosidase levels and reduces tissue glycogen in a mouse model of Pompe disease

✍ R. Khanna; R. Soksa; J. Feng; Y. Lun; A.C. Powe; J. Flanagan; H. Do; D.J. Lockha 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 39 KB

T.P.44 The pharmacological chaperone AT2

T.P.44 The pharmacological chaperone AT2220 increases the stability of recombinant human acid α-glucosidase and leads to greater tissue uptake and glycogen reduction in a mouse model of Pompe disease

✍ Valenzano, K.J.; Feng, J.; Soska, R.; Pellegrino, L.; Frascella, M.; Lun, Y.; Fl 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

G.P.11.05 The pharmacological chaperone

G.P.11.05 The pharmacological chaperone AT2220 increases trafficking, processing, and cellular activity of acid α-glucosidase and is a potential new treatment for Pompe disease

✍ A.C. Powe; J.F. Flanagan; R. Khanna; X. Wu; W. Liang; R. Dhulipala; T. Yin; K. T 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 49 KB